PRESCIENT NEUROPHARMA INC has a total of 24 patent applications. Its first patent ever was published in 1999. It filed its patents most often in Australia, United States and Canada. Its main competitors in its focus markets organic fine chemistry, pharmaceuticals and biotechnology are DOMPE PHA R MA SPA RES & MFG, REVIVA PHARMACEUTICALS INC and DOMPE PHA R MA SPA.
# | Country | Total Patents | |
---|---|---|---|
#1 | Australia | 6 | |
#2 | United States | 5 | |
#3 | Canada | 4 | |
#4 | Mexico | 4 | |
#5 | EPO (European Patent Office) | 3 | |
#6 | New Zealand | 1 | |
#7 | WIPO (World Intellectual Property Organization) | 1 |
# | Industry | |
---|---|---|
#1 | Organic fine chemistry | |
#2 | Pharmaceuticals | |
#3 | Biotechnology | |
#4 | Measurement |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Heterocyclic compounds | |
#3 | Acyclic or carbocyclic compounds | |
#4 | Medical preparations | |
#5 | Microorganisms | |
#6 | Peptides | |
#7 | Special acyclic compounds | |
#8 | Analysing materials |
# | Name | Total Patents |
---|---|---|
#1 | Curry Kenneth | 16 |
#2 | Commissiong John | 4 |
#3 | Pajouhesh Hossien | 3 |
#4 | Raibekas Andrei A | 3 |
#5 | Pajouhesh Hassan | 3 |
#6 | Commissiong John W | 2 |
#7 | Andrei A Raibekas | 1 |
Publication | Filing date | Title |
---|---|---|
AU2003266043A8 | Xanthenyl cubane analogs with activity at the metabotropic glutamate receptors | |
CA2441740A1 | Dopaminergic neuronal survival-promoting factors and uses thereof | |
EP1220681A2 | Opaminergic neuronal survival-promoting factors and uses thereof | |
CA2381260A1 | Novel 1,4-benzodiazepine compounds and derivatives thereof | |
MXPA02000610A | Methods for producing and preparing cells for cell therapy. | |
US7034055B1 | 2-aminoindane analogs | |
CA2376476A1 | 2-aminoindane analogs | |
CA2376470A1 | Novel aminoindanes | |
US6784202B1 | Cubane derivatives as metabotropic glutamate receptor agonists or antagonists and process for their preparation |